Chiesi bolsters rare disease portfolio via $1.3B Amryt buyout

Chiesi’s deal to acquire Amryt for almost $1.3 billion up front gives the pharma a portfolio of marketed drugs that includes metabolic therapies Juxtapid and Myalept, helping Chiesi to build its rare disease business.

Chiesi Farmaceutici S.p.A. is paying $14.50 per ADS up front for Amryt Pharma plc (NASDAQ:AMYT). Amryt’s shareholders are eligible to receive further payouts totaling $225 million, associated with contingent value rights worth $2.50 per share, if Amryt’s topical birch extract gel Filsuvez wins FDA approval and the agency issues a priority review voucher. FDA issued a complete response letter for Filsuvez in February 2022...